About Biofortuna
Biofortuna is a company based in Birkenhead (United Kingdom) founded in 2008 by Katherine Douglas, Nanette Douglas, and Rachel Douglas. Biofortuna has raised $21.58 million across 9 funding rounds from investors including Enterprise Ventures, Foresight Group and Merseyside Special Investment Fund. The company has 32 employees as of March 31, 2022. Biofortuna has completed 1 acquisition, including Cryoniss. Biofortuna operates in a competitive market with competitors including Novartis, Catalent, Surrozen, Biotage and Curia, among others.
- Headquarter Birkenhead, United Kingdom
- Employees 32 as on 31 Mar, 2022
- Founders Katherine Douglas, Nanette Douglas, Rachel Douglas
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biofortuna Limited
- Date of Incorporation 26 Feb, 2008
- Jurisdiction DEESIDE, WALES
-
Annual Revenue
$1.44 M (USD)-12as on Mar 31, 2018
-
Net Profit
-$1.34 M (USD)-32as on Mar 31, 2018
-
EBITDA
-$1.57 M (USD)-17as on Mar 31, 2018
-
Total Equity Funding
$21.58 M (USD)
in 9 rounds
-
Latest Funding Round
$303.19 K (USD), Grant
Feb 20, 2026
-
Investors
Enterprise Ventures
& 5 more
-
Employee Count
32
as on Mar 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Biofortuna
Biofortuna has successfully raised a total of $21.58M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $303.19 thousand completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biofortuna
Biofortuna has secured backing from 6 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Enterprise Ventures, Foresight Group and Merseyside Special Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A fund focused on supporting SMEs with alternative finance.
|
Locked | Locked | Locked | |
|
Early and Growth stage Venture Debt firm that does debt investments in the UK
|
Locked | Locked | Locked | |
|
Investment solutions are provided by Catapult Ventures for growth.
|
Locked | Locked | Locked |
Investor details for Biofortuna
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biofortuna
Biofortuna has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cryoniss.
Investment portfolio details for Biofortuna
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of biobanking services for life sciences industries
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for Biofortuna
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biofortuna
Detailed financials for Biofortuna
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biofortuna Comparisons
Peer comparison for Biofortuna
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biofortuna
Biofortuna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Biotage and Curia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
|
| Locked | Locked | Locked |
CDMO offering drug and biologics development services
|
|
| Locked | Locked | Locked |
Selective Wnt agonists are developed for human tissue regeneration.
|
|
| Locked | Locked | Locked |
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
|
| Locked | Locked | Locked |
Drug research, development, testing, and consulting services are provided.
|
|
| Locked | Locked | Locked |
Protein therapeutics are developed and manufactured by WuXi Biologics.
|
Detailed competitors of Biofortuna
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biofortuna
Complete news archive for Biofortuna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biofortuna
Biofortuna was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Biofortuna is headquartered in Birkenhead, United Kingdom. It is registered at Birkenhead, Merseyside, United Kingdom.
Biofortuna is a funded company, having raised a total of $21.58M across 9 funding rounds to date.
As of Mar 31, 2022, the latest employee count at Biofortuna is 32.
Annual revenue of Biofortuna is $1.44M as on Mar 31, 2018.
Biofortuna was established in 2008 in Birkenhead, United Kingdom, within the biotechnology sector. Operations focus on contract manufacturing for immunoassays and molecular diagnostics, complemented by regulatory services. These activities support diagnostic product development and compliance needs for clients in healthcare and life sciences. The company is led by co-founders Katherine Douglas, Nanette Douglas, and Rachel Douglas.
Biofortuna has made 1 acquisition, including Cryoniss.
Biofortuna has 6 investors. Key investors include Enterprise Ventures, Foresight Group, Merseyside Special Investment Fund, Catapult Ventures, and David Whitcombe.
The valuation of Biofortuna is $476.6M as of Aug 2018.